BeOne Medicines Ltd.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

ONC$424.00+1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated balance sheets as of December 31, 202 and

CONSOLIDATED BALANCE SHEETS

	As of December 31,
	Note	2025	2024
$ · $
Assets
Current assets:
Cash and cash equivalents		4,547,530	2,627,410
Accounts receivable, net		865,080	676,278
Inventories, net	11	608,227	494,986
Prepaid expenses and other current assets	11	212,752	192,919
Total current assets		6,233,589	3,991,593
Property, plant and equipment, net	8	1,641,678	1,578,423
Operating lease right-of-use assets	7	148,184	139,309
Intangible assets, net	9	62,704	51,095
Other non-current assets	11	102,418	160,490
Total non-current assets		1,954,984	1,929,317
Total assets		8,188,573	5,920,910
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable		479,035	404,997
Accrued expenses and other payables	11	1,109,120	803,713
Tax payable	10	41,625	25,930
Operating lease liabilities, current portion	7	20,698	17,576
Research and development cost share liability, current portion	3	64,345	111,154
Sale of future royalty liability, current portion	4	56,714	—
Short-term debt	12	57,293	851,529
Total current liabilities		1,828,830	2,214,899
Non-current liabilities:
Long-term debt	12	961,913	166,484
Sale of future royalty liability, non-current portion	4	850,242	—
Operating lease liabilities, non-current portion	7	52,940	44,277
Deferred tax liabilities	10	53,209	42,007
Research and development cost share liability, non-current portion	3	—	54,286
Other long-term liabilities	11	80,245	66,735
Total non-current liabilities		1,998,549	373,789
Total liabilities		3,827,379	2,588,688
Commitments and contingencies	20
Shareholders’ equity:
Ordinary shares, $0.0001 par value per share; 1,540,975,898 and 1,387,367,704 shares issued and 1,441,075,618 and 1,387,367,704 shares outstanding as of December 31, 2025 and 2024, respectively		144	138
Additional paid-in capital		12,759,137	12,087,908
Accumulated other comprehensive loss	16	(78,184)	(148,988)
Accumulated deficit		(8,319,903)	(8,606,836)
Total shareholders’ equity		4,361,194	3,332,222
Total liabilities and shareholders’ equity		8,188,573	5,920,910

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.